NVA237 treatment effects vs placebo
| NVA237 (LS means, 95% CI) | PBO (LS means, 95% CI) | NVA237–placebo (LS means diff, 95% CI) | p Value | |
| Endurance time (s) | ||||
| Day 1 | 490.9 (458.5 to 523.4) | 447.78 (415.1 to 480.5) | 43.1 (10.9 to 75.4) | <0.001 |
| Day 21 | 505.6 (466.6 to 544.7) | 416.70 (377.8 to 455.6) | 88.9 (44.7 to 133.2) | <0.001 |
| IC at isotime (l) | ||||
| Day 1 | 2.25 (2.18 to 2.31) | 2.02 (1.96 to 2.08) | 0.23 (0.17 to 0.28) | <0.001 |
| Day 21 | 2.22 (2.15 to 2.29) | 2.02 (1.95 to 2.09) | 0.20 (0.13 to 0.28) | <0.001 |
| Functional residual capacity (l) % predicted | ||||
| Day 1 | 4.41 (4.32 to 4.51) | 4.77 (4.67 to 4.86) | −0.36 (−0.49 to −0.22) | – |
| Day 21 | 4.32 (4.22 to 4.42) | 4.78 (4.68 to 4.87) | −0.46 (−0.58 to −0.33) | |
| Residual volume (l) | ||||
| Day 1 | 3.49 (3.38 to 3.59) | 3.92 (3.82 to 4.02) | −0.44 (−0.58 to −0.29) | – |
| Day 21 | 3.46 (3.36 to 3.55) | 3.95 (3.86 to 4.05) | −0.50 (−0.63 to −0.36) | |
| Total lung capacity (l) | ||||
| Day 1 | 7.01 (6.90 to 7.12) | 7.08 (6.97 to 7.19) | −0.07 (−0.22 to −0.08) | – |
| Day 21 | 6.86 (6.75 to 6.97) | 7.10 (6.99 to 7.21) | −0.25 (−0.39 to −0.10) | |
| Specific airway conductance (Sec (−1)*kP) | ||||
| Day 1 | 0.68 (0.65 to 0.71) | 0.41 (0.38 to 0.45) | 0.26 (0.22 to 0.30) | – |
| Day 21 | 0.66 (0.63 to 0.70) | 0.42 (0.39 to 0.46) | 0.24 (0.19 to 0.29) | |
| Trough FEV1 (l) | ||||
| Day 1 | 1.46 (1.43 to 1.49) | 1.35 (1.31 to 1.38) | 0.11 (0.06 to 0.16) | <0.001 |
| Day 21 | 1.44 (1.40 to 1.48) | 1.33 (1.29 to 1.37) | 0.11 (0.06 to 0.16) | <0.001 |